Back to results
US 2024/0385192 A1Published application
Use of a fuc-alpha(1-2)-gal glycan structure as a biomarker for bladder cancer
AssigneeUniogen Oy
InventorsMd Khirul ISLAM, Parvez SYED, Janne LEIVO, Kamlesh GIDWANI
Life of this patent
Estimating the term…
Abstract
A non-invasive diagnostics of cancers, such as bladder cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers, especially integrins.
Claims7
-13. (canceled)
A method of determining bladder cancer disease state in a subject, the method comprising:
- a) assaying a sample of a bodily fluid obtained from said subject for the level of integrin-presenting vesicles comprising a FUCα(1-2)Gal glycan structure, or for the level of integrin antigen comprising a FUCα(1-2)Gal glycan structure,
- b) comparing the assayed level obtained in step a) with that of a control sample or a predetermined threshold value, and
- c) determining the cancer disease state on the basis of said comparison.
Dependencies are inferred from the claim text.